

Heart Product References



Al-Azzawie H. F., Alhamdani M.-S. S. Hypoglycemic and antioxidant effect of oleuropein in alloxan-diabetic rabbits. *Life Sciences*. 2006;78(12):1371–1377.

Sato H., Genet C., Strehle A., et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from *Olea europaea*. *Biochemical and Biophysical Research Communications*. 2007;362(4):793–798.

Jemai H., Feki A. E. L., Sayadi S. Antidiabetic and antioxidant effects of hydroxytyrosol and oleuropein from olive leaves in alloxan-diabetic rats. *Journal of Agricultural and Food Chemistry*. 2009;57(19):8798–8804.

Eidi A., Eidi M., Darzi R. Antidiabetic effect of *Olea europaea* L. in normal and diabetic rats. *Phytotherapy Research*. 2009;23(3):347–350.

Cumaoglu A., Rackova L., Stefek M., Kartal M., Maechler P., Karasu Ç. Effects of olive leaf polyphenols against H₂O₂ toxicity in insulin secreting β -cells. *Acta Biochimica Polonica*. 2011;58(1).

Barbaro B., Toietta G., Maggio R., et al. Effects of the olive-derived polyphenol oleuropein on human health. *International Journal of Molecular Sciences*. 2014;15(10):18508–18524.

Dubey V. K., Patil C. R., Kamble S. M., et al. Oleonic acid prevents progression of streptozotocin induced diabetic nephropathy and protects renal microstructures in Sprague Dawley rats. *Journal of Pharmacology & Pharmacotherapeutics*. 2013;4(1):47–52.

Al-Qarawi A. A., Al-Damegh M. A., ElMougy S. A. Effect of freeze dried extract of *Olea europaea* on the pituitary-thyroid axis in rats. *Phytotherapy Research*. 2002;16(3):286–287.

Walker, A. F., Marakis, G., Simpson, E., Hope, J. L., Robinson, P. A., Hassanein, M., & Simpson, H. C. (2006). Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial. *The British journal of general practice : the journal of the Royal College of General Practitioners*, 56(527), 437–443.

Condorelli, G., Roncarati, R., Ross, J., Jr, Pisani, A., Stassi, G., Todaro, M., Trocha, S., Drusco, A., Gu, Y., Russo, M. A., Frati, G., Jones, S. P., Lefer, D. J., Napoli, C., & Croce, C. M. (2001). Heart-targeted overexpression of caspase3 in mice increases infarct size and depresses cardiac function. *Proceedings of the National Academy of Sciences of the United States of America*, 98(17), 9977–9982. <https://doi.org/10.1073/pnas.161120198>

Yoo, J. H., Liu, Y., & Kim, H. S. (2016). Hawthorn Fruit Extract Elevates Expression of Nrf2/HO-1 and Improves Lipid Profiles in Ovariectomized Rats. *Nutrients*, 8(5), 283. <https://doi.org/10.3390/nu8050283>

Nauman, M. C., & Johnson, J. J. (2019). Clinical application of bergamot (*Citrus bergamia*) for reducing high cholesterol and cardiovascular disease markers. *Integrative food, nutrition and metabolism*, 6(2), 10.15761/IFNM.1000249. <https://doi.org/10.15761/IFNM.1000249>

Maresz K. (2015). Proper Calcium Use: Vitamin K2 as a Promoter of Bone and Cardiovascular Health. *Integrative medicine (Encinitas, Calif.)*, 14(1), 34–39.

van Ballegooijen, A. J., & Beulens, J. W. (2017). The Role of Vitamin K Status in Cardiovascular Health: Evidence from Observational and Clinical Studies. *Current nutrition reports*, 6(3), 197–205. <https://doi.org/10.1007/s13668-017-0208-8>

Wang, H., Yang, Y. J., Qian, H. Y., Zhang, Q., Xu, H., & Li, J. J. (2012). Resveratrol in cardiovascular disease: what is known from current research?. *Heart failure reviews*, 17(3), 437–448. <https://doi.org/10.1007/s10741-011-9260-4>

Sungthong, B., Yoothaekool, C., Promphamorn, S., & Phimarn, W. (2020). Efficacy of red yeast rice extract on myocardial infarction patients with borderline hypercholesterolemia: A meta-analysis of randomized controlled trials. *Scientific reports*, 10(1), 2769. <https://doi.org/10.1038/s41598-020-59796-5>

Dyck, G., Raj, P., Zieroth, S., Dyck, J., & Ezekowitz, J. A. (2019). The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review. *International journal of molecular sciences*, 20(4), 904. <https://doi.org/10.3390/ijms20040904>

Dolinsky, V. W., & Dyck, J. R. (2014). Experimental studies of the molecular pathways regulated by exercise and resveratrol in heart, skeletal muscle and the vasculature. *Molecules*, 19(9), 14919-14947.

Raj, P., Louis, X. L., Thandapilly, S. J., Movahed, A., Zieroth, S., & Netticadan, T. (2014). Potential of resveratrol in the treatment of heart failure. *Life sciences*, 95(2), 63-71.

Penumathsa, S. V., & Maulik, N. (2009). Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. *Canadian journal of physiology and pharmacology*, 87(4), 275-286.

Zozina, V. I., Covantev, S., Goroshko, O. A., Krasnykh, L. M., & Kukes, V. G. (2018). Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem. *Current cardiology reviews*, 14(3), 164–174.
<https://doi.org/10.2174/1573403X14666180416115428>

Di Lorenzo, A., Iannuzzo, G., Parlato, A., Cuomo, G., Testa, C., Coppola, M., D'Ambrosio, G., Oliviero, D. A., Sarullo, S., Vitale, G., Nugara, C., Sarullo, F. M., & Giallauria, F. (2020). Clinical Evidence for Q10 Coenzyme Supplementation in Heart Failure: From Energetics to Functional Improvement. *Journal of clinical medicine*, 9(5), 1266.
<https://doi.org/10.3390/jcm9051266>

Rosenblum, H., Bikdeli, B., Wessler, J., Gupta, A., & Jacoby, D. L. (2020). Zinc Deficiency as a Reversible Cause of Heart Failure. *Texas Heart Institute journal*, 47(2), 152–154.
<https://doi.org/10.14503/THIJ-17-6586>

Little, P. J., Bhattacharya, R., Moreyra, A. E., & Korichneva, I. L. (2010). Zinc and cardiovascular disease. *Nutrition (Burbank, Los Angeles County, Calif.)*, 26(11-12), 1050–1057.
<https://doi.org/10.1016/j.nut.2010.03.007>

Chu, A., Foster, M., & Samman, S. (2016). Zinc Status and Risk of Cardiovascular Diseases and Type 2 Diabetes Mellitus-A Systematic Review of Prospective Cohort Studies. *Nutrients*, 8(11), 707. <https://doi.org/10.3390/nu8110707>